Session: Prevention, Screening, and Early Intervention in Primary Care: Opportunities and Challenges in the Era of the Affordable Care Act and Parity (Society for Prevention Research 22nd Annual Meeting)

3-039 Prevention, Screening, and Early Intervention in Primary Care: Opportunities and Challenges in the Era of the Affordable Care Act and Parity

Schedule:
Thursday, May 29, 2014: 1:15 PM-2:45 PM
Columbia C (Hyatt Regency Washington)
Theme: Large-scale Dissemination of Prevention Policies, Programs, and Practices
Symposium Organizer:
C. Hendricks Brown
Discussants:
Sheppard Gordon Kellam and Hilda Maria Pantin
Sixty-three million Americans are expected to receive increased services for mental health and drug abuse problems in January, 2014 through the Affordable Care Act and Parity legislation that mandates the delivery of evidence-based programs to address mental health and drug abuse.  While there are approved interventions for depression, smoking, and alcohol abuse that can now be reimbursed through Medicaid, there are no programs that the U.S. Preventive Services Task Force have identified as evidence-based for either illicit drug abuse or suicide screening and early intervention.  In this symposium, we address these challenges using two innovative approaches that begin with screening, followed by brief interventions and referrals.  First, we will present recent findings from the NIDA funded QUIT randomized trial in five Federally Qualified Health Care settings.  This program finds significant reduction in illicit drug use among those who screen positive for problem drug use using the ASSIST system, i.e. those who are most likely to benefit from a brief intervention.  This confirms that evidence for the efficacy of an approach that has been identified as successful for alcohol abuse, is potentially valuable for drug use as well.  Our second presenter will provide an implementation perspective from the point of view of the leadership of one of the country’s largest FQHC systems, AltaMed Health Services, which served as the sites for the QUIT efficacy trial.  Factors in the decision making of AltaMed are presented that are necessary to lead to wide scale adoption.  A third presentation discusses the use of a comprehensive system of screening and multistage intervention built especially around adolescent suicide that is now being administered in 5 emergency rooms and 25 primary care practices.  Implications for the implementation of these and related systems will be addressed by our discussants, who will provide perspectives on how population based prevention can be linked to such services.

* noted as presenting author
277
Integrating Mental Health into Primary Care
Guy S. Diamond, PhD, Drexel University
278
Project Quit: A Primary Care Based Screening and Brief Intervention Efficacy Trial to Reduce Risky Drug Use
Lillian Gelberg, MD, MSPH, University of California, Los Angeles; Ronald M. Andersen, PhD, University of California, Los Angeles; Barbara Leake, Phd, University of California, Los Angeles; Lisa Arangua, MPP, University of California, Los Angeles; Mani Vahidi, BA, University of California, Los Angeles; Kyle Singleton, BA, University of California, Los Angeles; Julia Yacenda-Murphy, BA, University of California, Los Angeles; Steve Shoptaw, PhD, University of California, Los Angeles; Michael F. Fleming, MD, MPH, Northwestern University; Sebastian E. Baumeister, PhD, University of Greifswald
279
Drug Abuse and Mental Health Innovations How Are Decisions Made at Altamed Health Services?
Michael E. Hochman, MD, MPH, AltaMed; Sandra Pisano, PsyD, AltaMed; Anjani Reddy, MD, University of California, Los Angeles; Lillian Gelberg, MD, MSPH, University of California, Los Angeles; Martin Serota, MD, AltaMed Health Services